Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab, Lenalidomide, and ICE for Relapsed/Refractory Large B-Cell Lymphoma
NCT05821088Phase 2Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Complete remission rate. Started Jun 2023; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05821088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821088.